JP2025513745A5 - - Google Patents
Info
- Publication number
- JP2025513745A5 JP2025513745A5 JP2024557632A JP2024557632A JP2025513745A5 JP 2025513745 A5 JP2025513745 A5 JP 2025513745A5 JP 2024557632 A JP2024557632 A JP 2024557632A JP 2024557632 A JP2024557632 A JP 2024557632A JP 2025513745 A5 JP2025513745 A5 JP 2025513745A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- antigen
- binding fragment
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2022/083269 | 2022-03-28 | ||
| CN2022083269 | 2022-03-28 | ||
| PCT/CN2023/084213 WO2023185778A1 (en) | 2022-03-28 | 2023-03-28 | Novel anti-fgfr2 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025513745A JP2025513745A (ja) | 2025-04-30 |
| JP2025513745A5 true JP2025513745A5 (enExample) | 2026-04-08 |
Family
ID=88199423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024557632A Pending JP2025513745A (ja) | 2022-03-28 | 2023-03-28 | 新規抗ｆｇｆｒ２抗体 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4499701A4 (enExample) |
| JP (1) | JP2025513745A (enExample) |
| KR (1) | KR20250042203A (enExample) |
| CN (1) | CN119110806A (enExample) |
| AU (1) | AU2023243773A1 (enExample) |
| CA (1) | CA3246949A1 (enExample) |
| IL (1) | IL315970A (enExample) |
| MX (1) | MX2024011805A (enExample) |
| WO (1) | WO2023185778A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025185559A1 (zh) * | 2024-03-04 | 2025-09-12 | 杭州中美华东制药有限公司 | 抗FGFR2b抗体、其抗体药物偶联物及其用途 |
| CN118772279B (zh) * | 2024-06-28 | 2025-03-25 | 北京普利米特生物科技有限公司 | 抗FGFR2b抗体或其抗原结合片段及其用途 |
| WO2026092428A1 (zh) * | 2024-10-28 | 2026-05-07 | 湖北生物医药产业技术研究院有限公司 | 无岩藻糖基化抗FGFR2b单抗 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014089193A1 (en) * | 2012-12-04 | 2014-06-12 | Aveo Pharmaceuticals, Inc. | Anti-fgfr2 antibodies |
| CN105452296B (zh) * | 2013-08-01 | 2020-09-25 | 戊瑞治疗有限公司 | 无岩藻糖基化抗fgfr2iiib抗体 |
| US9931401B2 (en) * | 2013-10-08 | 2018-04-03 | Daiichi Sankyo Company, Limited | Combination comprising anti-fibroblast growth factor receptor 2 (FGFR2) antibody and a tyrosine kinase inhibitor |
| US10881734B2 (en) * | 2015-04-20 | 2021-01-05 | Daiichi Sankyo Company, Limited | Monoclonal antibodies to human fibroblast growth factor receptor 2 (HFGFR2) and methods of use thereof |
| UA130250C2 (uk) * | 2018-10-05 | 2025-12-31 | Файв Прайм Терапьютикс, Інк. | Рідкий фармацевтичний склад та композиція на основі антитіла до fgfr2 |
| CN114846029A (zh) * | 2019-12-24 | 2022-08-02 | 迪哲(江苏)医药股份有限公司 | 新颖抗fgfr2b抗体 |
| US20230055566A1 (en) * | 2019-12-24 | 2023-02-23 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Novel anti-fgfr2b antibodies |
| WO2021129656A1 (en) * | 2019-12-24 | 2021-07-01 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Novel anti-fgfr2b antibodies |
-
2023
- 2023-03-28 CN CN202380031311.1A patent/CN119110806A/zh active Pending
- 2023-03-28 CA CA3246949A patent/CA3246949A1/en active Pending
- 2023-03-28 JP JP2024557632A patent/JP2025513745A/ja active Pending
- 2023-03-28 KR KR1020247035207A patent/KR20250042203A/ko active Pending
- 2023-03-28 IL IL315970A patent/IL315970A/en unknown
- 2023-03-28 WO PCT/CN2023/084213 patent/WO2023185778A1/en not_active Ceased
- 2023-03-28 EP EP23778143.0A patent/EP4499701A4/en active Pending
- 2023-03-28 AU AU2023243773A patent/AU2023243773A1/en active Pending
-
2024
- 2024-09-25 MX MX2024011805A patent/MX2024011805A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026041845A5 (enExample) | ||
| JP2022506072A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2020510422A5 (enExample) | ||
| JP2013502913A5 (enExample) | ||
| JP2022533538A5 (enExample) | ||
| JP2018506961A5 (enExample) | ||
| JP2024504390A5 (enExample) | ||
| JP2023543493A5 (enExample) | ||
| JP2023540526A5 (enExample) | ||
| JP2024016024A5 (enExample) | ||
| JP2023518153A5 (enExample) | ||
| JP2024534265A5 (enExample) | ||
| WO2023060277A1 (en) | Composition of multispecific antibodies targeting cdh17-expressing tumors and method of making and using thereof | |
| JP2022521305A (ja) | 抗ｐｄ－ｌ１抗体及びその使用 | |
| JP2024535930A5 (enExample) | ||
| JP2023545521A5 (enExample) | ||
| JP2024543822A5 (enExample) | ||
| IL312060A (en) | Bispecific CD16A binders | |
| JP2024525916A5 (enExample) | ||
| JP2023517794A5 (enExample) | ||
| JP2023533793A5 (enExample) | ||
| JP2024020436A5 (enExample) | ||
| JP2025508606A5 (enExample) | ||
| JP2025503229A5 (enExample) |